History of the CHO Cells
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Biomanufacturing Technology Roadmap
©BioPhorum Operations Group Ltd SUPPLY PARTNERSHIP MANAGEMENT BIOMANUFACTURING TECHNOLOGY ROADMAP SUPPLY PARTNERSHIP MANAGEMENT BPOG Technology Roadmap 1 ©BioPhorum Operations Group Ltd SUPPLY PARTNERSHIP MANAGEMENT Acknowledgments The following member company participants are acknowledged for their efforts and contributions in the production of this roadmap document. (* indicates non-member contributor) AstraZeneca Merck & Co. Inc., Kenilworth, NJ, USA Merck KGaA, Darmstadt, Germany Mike Kinley Adam Randall Kendall Nichols Bayer Pfizer Asahi Kasei Bioprocess Edgar Sur Jennifer Johns Kimo Sanderson Biogen Roche Thermo Fisher Scientific Dave Kolwyck Freia Funke Steve Gorfien Rhea Mahabir GSK Shire Iris Welch Alan Glazer BioPhorum Operations Group Mike McSweeney Alfred Keusch Bob Brooks Bela Green Janssen Avantor* Chris Calabretta Dave Lescinski* BPOG Technology Roadmap 2 ©BioPhorum Operations Group Ltd SUPPLY PARTNERSHIP MANAGEMENT Contents 1 Summary ..............................................................................................................................................................................................................5 2 Introduction .........................................................................................................................................................................................................6 2.1 Vision ....................................................................................................................................................................................................................................6 -
Rapid Vaccine Development & Biomanufacturing Using a Scalable
Rapid Vaccine Development & Biomanufacturing Using a Scalable, Non-viral Delivery Platform for Cell Engineering. James Brady, Weili Wang, Rama Shivakumar, Pachai Natarajan, Krista Steger, and Madhusudan Peshwa. MaxCyte, Gaithersburg, MD, USA. Abstract Researchers have looked to recombinant technologies to develop innovative types of vaccines and new cell culture-based means of production that offer shorter lead times and greater production flexibility while High Level Cell Viability and Transfection maintaining vaccine safety. Transient transfection offers a means of rapidly producing an array of proteins, Efficiencies including antibodies, vaccines, viral vectors, and virus-like particles (VLPs). Although a variety of transient transfection methods are available, most do not meet the requirements of scalability, consistency, and cell Figure 1. High Efficiency Transfection of Cell Types type flexibility for use in vaccine development and manufacturing. MaxCyte’s electroporation-based delivery Commonly Used for Protein and Vaccine Production. platform reproducibly transfects a broad range of biorelevant adherent and suspension cell types with high Various cells were transfected with 2 µg/1E6 cells of pGFP cell viabilities & transfection efficiencies using single-use processing assemblies for cGMP, “plug-and-play” DNA using the appropriate MaxCyte STX protocol. Cells production of recombinant proteins and vaccines. In this poster we present data for large-scale production were examined for GFP expression using fluorescence microscopy 24 hrs post electroporation (EP). of antibodies, recombinant antigens, VLPs, and lentiviral vectors using the MaxCyte STX® Scalable Transfection System. Data are presented for high-efficiency transfection of cells commonly used in protein production including CHO, HEK293, and insect cells--without the use of baculovirus--with a timeline of just a few days from plasmid to gram quantities of protein. -
Bioprocessing Asia 2018 Programme and Abstract Book
BPA BioProcessing Asia BioProcessing Asia 2018 Programme and Abstract Book Third International Conference LANGKAWI, MALAYSIA, 12–15 NOVEMBER 2018 Contents General Information 4 The BioProcessing Asia Conference Series 7 Scientific Advisory Committee 8 Sponsors 10 Programme 18 Poster list 24 Abstracts 26 Session 1 27 Session 2 30 Session 3 33 Session 4 37 Session 5 41 Session 6 45 Poster Session 7 49 Welcome to the Third International BioProcessing Asia Conference at the Langkawi International Convention Centre, Langkawi, Malaysia It is a great pleasure to welcome you to the third meeting in the BioProcessing Asia Conference Series. This Conference continues the trend set by the two previous BPA conferences in 2014 and 2016 in exploring themes and topics focused on the contribution of bioprocessing towards the development and manufacture of affordable biopharmaceutical products in Asia. Of particular importance at this conference is the contribution made by our Scientific Advisory Committee on the identification of specific current trends in the field. This input has led to the selection of six Oral Sessions that cover important aspects of bioprocessing ranging from disease treatments, innovations in technology, vaccine design and development, the changing environment of plasma products, disruptive manufacturing strategies and the evolving regulatory environment in Asia. These topics are further developed and explored in the Poster Session where, as in the past, more detailed discussions and the exploration of ideas without the usual constraints of time can be pursued. We are fortunate to have attracted several outstanding Keynote and Focus lecturers to the meeting including Dr Ashok Kumar, President of IPCA Ltd’s R&D Centre in Mumbai and Dr Subash Kapre, Director Emeritus at the Serum Institute of India and from Inventprise, USA, who, together with the distinguished Session Chairs will set the tone and lead the discussions on salient areas of bioprocessing. -
Scale and High-Quality Human T Cells Production Jianfa Ou1, Yingnan Si1, Yawen Tang1, Grace E
Ou et al. Journal of Biological Engineering (2019) 13:34 https://doi.org/10.1186/s13036-019-0167-2 RESEARCH Open Access Novel biomanufacturing platform for large- scale and high-quality human T cells production Jianfa Ou1, Yingnan Si1, Yawen Tang1, Grace E. Salzer1, Yun Lu1, Seulhee Kim1, Hongwei Qin2, Lufang Zhou3 and Xiaoguang Liu1* Abstract The adoptive transfer of human T cells or genetically-engineered T cells with cancer-targeting receptors has shown tremendous promise for eradicating tumors in clinical trials. The objective of this study was to develop a novel T cell biomanufacturing platform using stirred-tank bioreactor for large-scale and high-quality cellular production. First, various factors, such as bioreactor parameters, media, supplements, stimulation, seed age, and donors, were investigated. A serum-free fed-batch bioproduction process was developed to achieve 1000-fold expansion within 8 days after first stimulation and another 500-fold expansion with second stimulation. Second, this biomanufacturing process was successfully scaled up in bioreactor with dilution factor of 10, and the robustness and reproducibility of the process was confirmed by the inclusion of different donors’ T cells of various qualities. Finally, T cell quality was monitored using 12 surface markers and 3 intracellular cytokines as the critical quality assessment criteria in early, middle and late stages of cell production. In this study, a new biomanufacturing platform was created to produce reliable, reproducible, high-quality, and large-quantity (i.e. > 5 billion) human T cells in stirred-tank bioreactor. This platform is compatible with the production systems of monoclonal antibodies, vaccines, and other therapeutic cells, which provides not only the proof-of-concept but also the ready-to-use new approach of T cell expansion for clinical immune therapy. -
Copyright by Paul Harold Rubinson 2008
Copyright by Paul Harold Rubinson 2008 The Dissertation Committee for Paul Harold Rubinson certifies that this is the approved version of the following dissertation: Containing Science: The U.S. National Security State and Scientists’ Challenge to Nuclear Weapons during the Cold War Committee: —————————————————— Mark A. Lawrence, Supervisor —————————————————— Francis J. Gavin —————————————————— Bruce J. Hunt —————————————————— David M. Oshinsky —————————————————— Michael B. Stoff Containing Science: The U.S. National Security State and Scientists’ Challenge to Nuclear Weapons during the Cold War by Paul Harold Rubinson, B.A.; M.A. Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin August 2008 Acknowledgements Thanks first and foremost to Mark Lawrence for his guidance, support, and enthusiasm throughout this project. It would be impossible to overstate how essential his insight and mentoring have been to this dissertation and my career in general. Just as important has been his camaraderie, which made the researching and writing of this dissertation infinitely more rewarding. Thanks as well to Bruce Hunt for his support. Especially helpful was his incisive feedback, which both encouraged me to think through my ideas more thoroughly, and reined me in when my writing overshot my argument. I offer my sincerest gratitude to the Smith Richardson Foundation and Yale University International Security Studies for the Predoctoral Fellowship that allowed me to do the bulk of the writing of this dissertation. Thanks also to the Brady-Johnson Program in Grand Strategy at Yale University, and John Gaddis and the incomparable Ann Carter-Drier at ISS. -
So, What Is Biomanufacturing?
Bioscience Industry Fellowship Project 2014 Presentations S Table of Contents Example of Course Development for STEM Slides 3-14 Community College Instructors Heather King; Igor Kreydin What does “Boot Camp” mean? Slides 15-61 Julie Ellis; Ezekiel Barnes Recruitment Plan for Biosciences Slides 62-66 Scott Gevart; Daymond Lindell Bioscience Awareness: Using what we know to Slides 67-93 build for tomorrow’s sustainability Savitha Pinnepalli; Jude Okoyeh BIOSCIENCES INDUSTRY FELLOWSHIP PROGRAM JUNE 2-27, 2014 Example of Course Development for STEM Community College Instructors (Based on BIFP Experience) Heather King Igor Kreydin Developmental Math Instructor STEAM Instructor Forsyth Technical Community College, NC Roxbury Community College, MA [email protected] [email protected] Modern Industry 2012 Educational Profile for Biotechnology Employees in NC High School 4% High School plus Certificate 10% 17% Associates in Science or 13% Associates in Applied Science Bachelor of Arts or Science 43% 13% Master of Arts or Science Doctorate NCGE-North Carolina in the Global Economy Project, http://www.ncglobaleconomy.com/NC_GlobalEconomy/biotechnology/overview.shtml In every math class you will hear … Why do I need to know this? When will I ever use this? In every science class you will hear … Did I learn how to do this in my math class? Don’t Let Your Students Get Stuck Here. Make Math Relevant! Basic Mathematical Concepts Equations Proportions Ratios of Lines Percents Exponents Basic Biotechnology Solving Equations Statistics Applications Graphs Fractions Scientific Formulas Conversions Notation Expressions, Linear Equations & Inequalities Dilutions of Solutions Forsyth Technical Community College Suppose you have a stock TGS electrophoresis buffer solution that is used in a protein profiler investigation of fish. -
Careers in Biomanufacturing
mapping your future: EXPLORING CAREERS IN BIOMANUFACTURING An Educational Module for Middle School and High School Teachers and Students Prepared by the North Carolina Association for Biomedical Research under contract with the North Carolina Biotechnology Center July 2006 mapping your future: EXPLORING CAREERS IN BIOMANUFACTURING This educational module was prepared by: The North Carolina Association for Biomedical Research (NCABR) P.O. Box 19469 Raleigh, NC 27619-9469 919-785-1304 http://www.ncabr.org Contact NCABR to obtain additional copies. © 2006 North Carolina Association for Biomedical Research. All rights reserved. mapping your future: EXPLORING CAREERS IN BIOMANUFACTURING ACKNOWLEDGEMENTS INTRODUCTION UNIT I: BIOTECHNOLOGY AND ITS APPLICATIONS A. What is Biotechnology? . 4 B. Biotechnology Timeline. 5 Student Activity: Biotech Timeline . 7 C. Practical Applications of Biotechnology . 12 Student Activity: Create a Logo. 18 Student Activity: Make a Yeast Incubator . 20 Student Activity: DNA Extraction From Yeast . 24 UNIT II: FROM LAB TO MARKET: DRUG DISCOVERY AND MANUFACTURING A. How a New Drug Gets to Market — An Overview . 28 B. Clinical Trials — A Closer Look . 29 C. The Pharmaceutical and Biopharmaceutical Industries — Regulated for Safety and Quality. 31 Student Activity: New Drug Development . 33 D. Producing a Pharmaceutical or Biopharmaceutical — The Manufacturing Process. 38 E. What Quality Means and Why It Matters . 39 F. Standard Operating Procedure (SOP) and Regulations . 41 Student Activity: Say What You Do and Do What You Say. 42 UNIT III: BIOMANUFACTURING CAREER OPPORTUNITIES A. Biotechnology Generates Opportunities . 48 B. Seizing the Opportunity . 49 C. On the Job — Typical Biomanufacturing Job Positions . 50 Student Activity: A Day in the Life of Six Biomanufacturing Employees . -
A Breakthrough High-Performance Viral Vaccines Biomanufacturing Platform to Countermeasure Epidemic Threats
A breakthrough high-performance viral vaccines biomanufacturing platform to countermeasure epidemic threats Webinar Dr. Tania Pereira Chilima, deputy CTO Brussels, May 2020 ©2020 Univercells Technologies. All Rights reserved The next evolution of biomanufacturing Univercells Technologies designs and delivers state-of-the-art high- performance, scalable bioproduction technologies for viral products Univercells Technologies genesis 2013 2020 Mission Make biologics affordable Design and deliver the next evolution and available to all! of biomanufacturing History > Created in 2013 in Belgium > Univercells subsidiary created in 2020 > Capitalizing on unmatched bioprocessing > Revolutionizing bioprocess by commercializing and engineering expertise next generation viral manufacturing technologies Focus > Offering technologies, services and > Intensification of high-performance operations & turnkey solutions to alleviate the chaining of unit steps into an integrated process industry’s current shortfall in supply of cell > Key assets: NevoLine™ platform & scale-X™ and gene therapies, vaccines and bioreactor biotherapeutics Source: Univercells Technologies ©2020 Univercells Technologies. All Rights reserved 2 Univercells technologies capitalizes on a strong team of experts and a global footprint for equipment dissemination and client support Capabilities Engineers and and expertise 60+ process specialists Employees R&D > Assembly, manufacturing > Validation (FAT) Engineering services > Supply and Logistics for installation, training and maintenance -
Pas&Uena, California At\F;Ust 30, 1956 an Application to T:C.E National Science Fouldation for a Grant to Support Research I
CALIFORNIA INSTITUTE OF TECBIH ,r,QGY Pas&uena, California At\f;ust 30, 1956 An Application to t:C.e Nat ional Science FouLdation For a Grant to Support Research in Theoretical and Quantitative Biology Institutions: The California Institute of Technolo~J The University of Chicago University of Colorado School of Med:Lcine New York University College of Medicine The Rockefeller Institute for rredical Research Administrative Direction: Division of Biology California Institute of Technology, Pasadena; Califo:;.~nia Total Budmet and Duration: $105,857 for five years or $211,710 for ten years · Starting date: July 1, 1957 Administrative officer to whom payments should be mailed: George Vl. Green, Vice President :for Business Affairs California Institute of Technology Pasadena, California Approved for the Ca.lifor.aia Inc-.ti1~ te of Techno~ ogy! /s/ G. W. ·Beadle G. W. · Bee.dle, Cha~2"lllD.,1, Division· of Biology /s/ G. rl. Green G. W. Green-,~V~ic-e~Pr::--e-.s-i:::-:c:fe:otforBusineoss- Affairs /s/ L . A. Du13r1dge ---- L. A. DuBrid~e, Prosident--~--~---------------- Approved for the University of Chicago: ------·--------·--------------- --------------- Approved for the University of Colorado S<::boal:o:- !~d.ic,ine : -----·------------------------ Approved for New York University College of i<'..ed1cin~; ------- ---·~- ------------- ------------------~------------------------------ Approved for The Rockefeller Irstit'-'te for t.ied.iceJ. Recearch: ~--... -~-------------------- Research in Theoretical ~~~ Background: In 1946, after a distinguis~d career in physics, Professor Leo Szilard became an active reseaxch worker in biology. As such, he has bad great influence, not only ·because of his own research efforts, which were to a large extent made in collaboration with Professor Aaron Novick of the University of Chicago, but a l so because of his catalytic influence on workers in other laboratories. -
Annual Report
2010 ANNUAL REPORT years 6 of Fighting Kidney Disease 2010 BY THE NUMBERS TABLE OF CONTENTS Leadership Message ................................................... 2 32,000 30,000 $3.5MILLION 60th Anniversary .......................................................... 3 healthcare professionals people across the U.S. in NKF grants to took NKF continuing received free kidney researchers and education courses. screenings through scientists. Patient Advocacy ....................................................... 6 the NKF. Organ Donation ................................................................ 7 years Early Detection ...........................................................10 MILLION MILLION 4.2 $3 15,000 Public Education ........................................................12 people seeking health in direct assistance to kidney patients, family 6 information visited patients. members and professionals kidney.org. participated in NKF’s Professional Education ..............................................14 Take Action e-Advocacy Network. In 2010, the National Kidney Research .....................................................................16 Foundation celebrated Global Initiatives ........................................................18 5,000 60 years of service to 75,000 people with kidney disease, Fundraising ........................................................................ 19 transplant athletes, donors, kidney patients, their families and kidney donor families & supporters families and friends 60 Years of NKF -
Theodore T. Puck
NATIONAL ACADEMY OF SCIENCES THEODORE THOMAS PUCK 1 9 1 6 — 2 0 0 5 A Biographical Memoir by DAVID PATTERSON Any opinions expressed in this memoir are those of the author and do not necessarily reflect the views of the National Academy of Sciences. Biographical Memoir COPYRIGHT 2009 NATIONAL ACADEMY OF SCIENCES WASHINGTON, D.C. THEODORE THOMAS PUCK September 24, 1916–November 6, 2005 BY DAVID PATTERSON HEODORE PUCK WAS ONE of those rare scientists who es- Tsentially created a new discipline, somatic cell genetics. His work made possible much of modern mammalian cell molecular genetics. He devised the first practical method to accomplish single-cell plating of mammalian cells with a high (indistinguishable from 100 percent in some cases) plating efficiency (1955). What is not so widely recognized are his contributions to the more technical aspects of this discipline; for example, he and his colleagues designed and built the first really practical CO2 incubators for growing mammalian cells as individual colonies (1962,2). The incubators we all currently use, although technologically much different from Ted’s original design, are based on the principles that he established. Ted’s lab was still building incubators when I arrived in 1971, and in my experience these incubators worked bet- ter than anything available to this day. He recognized early on the importance of devising well-defined, and hopefully completely defined, growth media for mammalian cells. He was certainly not the first to come to this realization, but he and his colleagues, especially Richard Ham and Gordon Sato, were among the most successful (Ham 1965; Barnes and Sato, 1980). -
Crisci, Mazzurana 2016 Amphibious Scientist
“REASSEMBLING THE SOCIAL” IN ENTREPRENEURIAL INNOVATION AND ACADEMIC ENTREPRENEURSHIP STUDIES: THE “AMPHIBIOUS SCIENTIST” PHENOMENON Francesco Crisci, Paola A.M. Mazzurana (*) University of Udine (Italy) First draft (September-October 2015) A short (and quite different) version of this work was published in: Fast growing new firms in a slow growth economy: Institutional conditions for innovation, eds. Francesca Visintin and Daniel Pittino, Edward Elgar Publishing (Chapter 8) INTRODUCTION THEORETICAL CONTEXT Entrepreneurial innovation Academic entrepreneurship EMPIRICAL CONTEXTS METHODS Data Collection Analytical Process: ANT as Research Strategy FINDINGS “Attack of the Cloners”: DBF emergence (1968-1981) An Organizational Hybrid: IGA e IGA-Tech as a DBF variant DISCUSSION E CONCLUSION How the biotech market becomes a(n) (arti)fact (1968-1981) Amphibious entrepreneurs and narrative dimensions of academic entrepreneurship Implications and future research REFERENCES (*) This paper is a collaborative effort as reflected in the alphabetical ordering of authorship. We thank Miranda Lewis and Martina Romano who have served as junior researchers for this case study in the first steps of data collecting and data analysis. 1 INTRODUCTION This paper aims to "translate" the research strategy of the Actor-Network Theory (ANT) in Management and Organization Studies (MOS), with reference to research on Academic Entrepreneurship. First, the concept of “amphibious scientist”, recalled in the title, was introduced in a research program that addresses the emergence of markets and organizations from a sociological perspective. John Padgett and Walter Powell (2012) have investigated the development of biotechnologies, the operation of laboratories dedicated to life sciences and the role of venture capitalists (VCs) in front of the possibilities offered by the new technologies of genetic manipulation developed in the academic field.